Rhythm Technologies (Nasdaq: IRTC) announced results from two large, real-world analyses demonstrating the benefits of its ...

SAN FRANCISCO, March 31, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced results from two large real-world ...

Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...

Technologies announced results from two large real-world retrospective analyses presented at the American College of Cardiology, ...

The Zio monitor's enhanced design is 23% thinner, 62% lighter and 72% smaller, offering better patient comfort and 99% compliance with wear times. The Zio system is supported by over 100 peer ...

The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio ...

The company achieved significant milestones, including its first 1 million patients registered for Zio Monitor and crossing 2 ...

Zio XT has been recommended by NICE as an option for people with suspected cardiac arrhythmias who would benefit from ECG monitoring for longer than 24 hours, as a lighter, discreet alternative to ...

Drawing on data from more than 1.1 million patients who used iRhythm’s Zio® long-term continuous monitoring (LTCM) ECG devices, these studies demonstrate that short-term (24–48-hour ...